This clinical trial is studying geographic atrophy, a form of eye damage that can happen with age-related macular degeneration. The treatment being tested is FWY003, taken by mouth as a capsule. Some participants will receive placebo instead. The purpose of the study is to see how different doses of FWY003 may affect the eye disease and to check its safety.

The study will compare FWY003 with placebo in people with this eye condition. It is a randomized study, which means the treatment is assigned by chance, and double masked, which means neither the participants nor the study team know who receives FWY003 or placebo during the study. Over time, the study follows changes in the damaged area in the eye and also watches for side effects and other health changes. The study lasts for many months and includes regular visits during which eye health and general well-being are reviewed.